

DAFTAR PUSTAKA

- Bologna-Molina, R., Mosqueda-Taylor, A., Molina-Frechero, N., Mori-Estevez, A.D., Sánchez-Acuña G., 2013. Comparison of The Value of PCNA and Ki-67 as Markers of Cell Proliferation in Ameloblastic tumors. *Medicina Oral, Patologia Oral y Cirugia Bucal*, 18(2). Pp: e174-e179.
- Chen, V.W., Ruiz, B., Killeen, J.L., Coté, T.R., Wu, X.C., Correa, C.N., 2003. Pathology and Classification of Ovarian Tumors. *Cancer*, 97(10 Suppl), pp.2631-2642.
- Davis, M. et al., 2014. Comparison of Clinical Outcomes of Patients with Clear Cell and Endometrioid Ovarian Cancer Associated with Endometriosis to Papillary Serous Carcinoma of The Ovary. *Gynecologic Oncology*, 132(3), pp.760-766.
- De Azambuja, E. et al., 2007. Ki-67 as Prognostic Marker in Early Breast Cancer: A Meta-analysis of Published Studies Involving 12,155 Patients. *British Journal of Cancer*, 96(10), pp.1504-1513.
- Funk, J.O., Waga, S., Harry, J.B., Espling, E., Stillman, B., Galloway, D., 1997. Inhibition of CDK Activity and PCNA-dependent DNA Replication p21 is Blocked by Interaction with The HPV-16 E7 Oncoprotein. *Genes and Development*, 11(16), pp.2090-2100.
- Gadducci, A. et al., 2009. Serum and Tissue Biomarkers as Predictive and Prognostic Variables in Epithelial Ovarian Cancer. *Critical Reviews in Oncology/Hematology*, 69(1), pp.12-27.
- Georgescu, C. V., Florescu, M., Simionescu, C., 1999. Value of Immunohistochemistry in Confirming Undifferentiated Ovarian Carcinomas. *Romanian Journal of Morphology and Embryology = Revue Roumaine de Morphologie et Embryologie*, 45, pp.133-142.

- Giurgea, L.N., Ungureanu, C., Mihailovici, M.S., 2012. The Immunohistochemical Expression of p53 and Ki67 in Ovarian Epithelial Borderline Tumors. Correlation with Clinicopathological Factors. *Romanian Journal of Morphology and Embryology*, 53(4), pp.967-973.
- Guzińska-Ustymowicz, K., Pryczynicz, A., Kemona, A., Czyzewska, J., 2009. Correlation Between Proliferation Markers: PCNA, Ki-67, MCM-2 and Antiapoptotic Protein Bcl-2 in Colorectal Cancer. *Anticancer Research*, 29(8), pp.3049-3052.
- Hamilton, W., Peters, T.J., Bankhead, C., Sharp, D., 2009. Risk of Ovarian Cancer in Women with Symptoms in Primary Care: Population Based Case-control Study. *BMJ (Clinical research ed.)*, 339, pp.b2998.
- Hayat, M.A., 2010. Ovarian Cancer. *Methods of Cancer Diagnosis, Therapy, and Prognosis*, 6, pp.5-9.
- Jonat, W. & Arnold, N., 2011. Is the Ki-67 Labelling Index Ready for Clinical Use? *Annals of Oncology*, 22(3), pp.500-502.
- Jones, R.L. et al., 2009. The Prognostic Significance of Ki67 Before and After Neoadjuvant Chemotherapy in Breast Cancer. *Breast Cancer Research and Treatment*, 116(1), pp.53-68.
- Junquiera, L.C., Caeneiro, J. 2005. Basic Histology Text and Atlas. McGraw Hill. United States.
- Karuppayil, S.M., Moran, E., Gokul, M., 1998. Differential Regulation of p53-dependent and -independent Proliferating Cell Nuclear Antigen Gene Transcription by 12 O HRA Oncoprotein Requires CBP. *The Journal of Biological Chemistry*, 273(28), pp.17303-17306.
- Klintman, M., Bendahl, P.O., Grabau, D., Lövgren, K., Malmström, P., Fernö, M., 2010. The Prognostic Value of Ki67 is Dependent on Estrogen Receptor Status and Histological Grade in Premenopausal Patients with

- Node-negative Breast Cancer. *Modern pathology: An Official Journal of The United States and Canadian Academy of Pathology, Inc*, 23(2), pp.251-259.
- Köbel, M. et al., 2008. Ovarian Carcinoma Subtypes are Different Diseases: Implications for Biomarker Studies. *PLoS Medicine*, 5(12), pp.1749-1760.
- Komiyama, S.I., Aoki, D., Katsuki, Y., Nozawa, S., 2006. Proliferative Activity of Early Ovarian Clear Cell Adenocarcinoma Depends On Association with Endometriosis. *European Journal of Obstetrics Gynecology and Reproductive Biology*, 127(1), pp.130-136.
- Korkolopoulou, P., Oates, J., Kittas, C., Crocker, J., 1994. p53, c-myc p62 and Proliferating Cell Nuclear Antigen (PCNA) Expression in Non-Hodgkin's Lymphomas. *Journal of Clinical Pathology*, 47, pp.9-14.
- Kumar, V., Abbas, A. K., Aster J. C., 2013. Female Genital System and Breast. *Robbins and Cotran Pathologic Basic of Disease*. 9 edn. Elsevier Saunder, Philadelphia, pp.695-698.
- Kurman, R. & Shih, I., 2010. The Origin and Pathogenesis of Epithelial Ovarian Cancer- A Proposed Unifying Theory. *The American Journal of Surgical Pathology*, 34(3), pp.433-443.
- Levanon, K., Crum, C., Drapkin, R., 2008. New Insights Into The Pathogenesis of Serous Ovarian Cancer and Its Clinical Impact. *Journal of Clinical Oncology*, 26(32), pp.5284-5293.
- Le Page, C., Huntsman, D.G., Provencher, D.M., Mes-Masson, A.M., 2010. Predictive and Prognostic Protein Biomarkers in Epithelial Ovarian Cancer: Recommendation for Future Studies. *Cancers*, 2(2), pp.913-954.
- Luporsi, E. et al., 2012. Ki-67: Level of Evidence and Methodological Considerations for Its Role in The

- Clinical Management of Breast Cancer: Analytical and Critical Review. *Breast Cancer Research and Treatment*, 132(3), pp.895-915.
- Oemiati, R., Rahajeng, E. & Kristanto, A.Y., 2011. Prevalensi Tumor dan Beberapa Faktor yang Mempengaruhinya di Indonesia. *Buletin Penelitian Kesehatan*, 39(4), pp.190-204.
- Paunesku, T. et al., 2001. Proliferating Cell Nuclear Antigen (PCNA): Ringmaster of The Genome. *International journal of radiation biology*, 77(10), pp.1007-1021.
- Pectasides, D., Pectasides, E., Psyrri, A., Economopoulos, T., 2006. Treatment Issues in Clear Cell Carcinoma of The Ovary: A Different Entity? *Oncologist*, 11(10), pp.1089-94.
- Reitmaier, M., Rudlowski, C., Biesterfeld S., Rath, W., Schröder, W., 2000. [Comparative Studies on The Biological Significance of The Marker for Proliferation Ki-67-Antigen and PCNA in Primary Ovarian Carcinoma]. *Zentralbl Gynakol*, 122(7), pp.361-367.
- Rubin, E. et al., 2014. The Female Reproductive System. *Essentials of Rubin's Pathology*. 6 edn. Lippincott Williams & Wilkins, Philadelphia, pp.518-523.
- Sajeevan, T. et al., 2014. Immunohistochemical Study of p53 and Proliferating Cell Nuclear Antigen Expression in Odontogenic Keratocyst and Periapical Cyst. *Journal of Pharmacy and Bioallied Sciences*, 6(5), p.52.
- Siegel, R., Naishadham, D. & Jemal, A., 2012. Cancer Statistics, 2012. *CA: A Cancer Journal for Clinicians*, 62(1), pp.10-29.
- Tan, D.S.P. & Kaye, S., 2007. Ovarian Clear Cell Adenocarcinoma: A Continuing Enigma. *Journal of clinical pathology*, 60(4), pp.355-360.

- Thomas, H. et al., 1995. Proliferating Cell Nuclear Antigen (PCNA) Immunostaining-A Prognostic Factor in Ovarian Cancer? *British journal of cancer*, 71(2), pp.357-362.
- Tortora, G. J., & Derrickson, B.H., 2011. The Reproductive Systems. *Principle Anatomy and Physiology*. 13 edn. John Wiley&Sons, Asia, pp.1143-1150.
- Widagdo, R., 2009. *Angka Harapan Hidup Penderita Kanker Ovarium Rumah Sakit Sardjito*. Bagian Obstetri dan Ginekologi FK UGM, Yogyakarta.
- Yerushalmi, R., Woods, R., Ravdin, P.M., Hayes, M.M., Gelmon, K., 2010. Ki67 in Breast Cancer: Prognostic and Predictive Potential. *The Lancet Oncology*, 11(2), pp.174-183.
- Zhong, W. et al., 2008. Ki-67 and PCNA Expression in Prostate Cancer and Benign Prostatic Hyperplasia. *Clinical and investigative medicine. Medecine clinique et experimentale*, 31(1), pp.E8-E15.